JP2024063016A5 - - Google Patents

Info

Publication number
JP2024063016A5
JP2024063016A5 JP2024017576A JP2024017576A JP2024063016A5 JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5 JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024017576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024063016A (ja
Filing date
Publication date
Priority claimed from GBGB1802487.7A external-priority patent/GB201802487D0/en
Application filed filed Critical
Publication of JP2024063016A publication Critical patent/JP2024063016A/ja
Publication of JP2024063016A5 publication Critical patent/JP2024063016A5/ja
Pending legal-status Critical Current

Links

JP2024017576A 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト Pending JP2024063016A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1802487.7A GB201802487D0 (en) 2018-02-15 2018-02-15 Cytokine combination therapy
GB1802487.7 2018-02-15
JP2020543512A JP7808430B2 (ja) 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト
PCT/EP2019/053890 WO2019158728A1 (en) 2018-02-15 2019-02-15 Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020543512A Division JP7808430B2 (ja) 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2024063016A JP2024063016A (ja) 2024-05-10
JP2024063016A5 true JP2024063016A5 (enExample) 2026-01-22

Family

ID=61783635

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543512A Active JP7808430B2 (ja) 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト
JP2024017576A Pending JP2024063016A (ja) 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020543512A Active JP7808430B2 (ja) 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Country Status (9)

Country Link
US (2) US12030949B2 (enExample)
EP (1) EP3752529A1 (enExample)
JP (2) JP7808430B2 (enExample)
CN (1) CN112041342B (enExample)
AU (1) AU2019221627B2 (enExample)
CA (1) CA3088734A1 (enExample)
GB (1) GB201802487D0 (enExample)
IL (1) IL276344A (enExample)
WO (1) WO2019158728A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CN116323659A (zh) * 2020-06-12 2023-06-23 北京伟德杰生物科技有限公司 融合多肽
CA3190486A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10 receptor binding molecules and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
KR102697769B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
CN114605539B (zh) * 2020-12-09 2024-01-02 南京融捷康生物科技有限公司 人源化的抗IL-4Rα单域抗体及其应用
WO2022150791A2 (en) * 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to il2 receptor binding
CN114805572B (zh) * 2021-01-22 2022-12-13 上海济煜医药科技有限公司 抗原结合蛋白及其应用
KR20240107348A (ko) * 2022-05-23 2024-07-09 리제네코어 바이오테크 컴퍼니 리미티드 안정적인 항체 치료제
CN116606375B (zh) * 2023-07-03 2025-10-03 珠海瑞思普利医药科技有限公司 抗人白介素5纳米抗体及其应用
WO2026020024A1 (en) * 2024-07-19 2026-01-22 Bambusa Therapeutics, Inc. Multispecific binding agents and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
US20110008326A1 (en) 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
KR20110126748A (ko) 2009-04-07 2011-11-23 로슈 글리카트 아게 이중특이적 항-erbb-1/항-c-met 항체
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
EA028899B1 (ru) 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2825559B1 (en) 2012-03-13 2019-02-27 Novimmune SA Readily isolated bispecific antibodies with native immunoglobulin format
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2927321B1 (en) 2012-11-27 2021-02-17 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2922979A1 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
PT3049439T (pt) 2013-09-26 2020-03-31 Ablynx Nv Nanocorpos biespecíficos
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
PT3613432T (pt) * 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy

Similar Documents

Publication Publication Date Title
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2026012786A5 (enExample)
JP2024063016A5 (enExample)
JP2023113641A5 (enExample)
JP2025023938A5 (enExample)
JP2024037765A5 (enExample)
JP2023113681A5 (enExample)
JP2025106258A5 (enExample)
JP2023153863A5 (enExample)
JP2023164986A5 (enExample)
JP2024156705A5 (enExample)
JP2023134519A5 (enExample)
JP2025118771A5 (enExample)
JP2025038009A5 (enExample)
JP2024088648A5 (enExample)
JP2023103231A5 (enExample)
JP2025143267A5 (enExample)
JP2024160274A5 (enExample)
JP2023139025A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2024038101A5 (enExample)
JP2023100679A5 (enExample)
JP2025163046A5 (enExample)